Tin tức & Cập nhật
Xem bài viết Dược
Xem
Rivaroxaban for prophylactic anticoagulation in COVID-19 strikes out
The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.
Fixed-dose combo tackles PD symptoms while minimizing daytime sleepiness
P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
